Literature DB >> 22850289

J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.

Masahiro Yasaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22850289     DOI： 10.1253/circj.cj-12-0923

Source DB:  PubMed          Journal:  Circ J        ISSN： 1346-9843            Impact factor:   2.993


× No keyword cloud information.
  3 in total

Review 1.  Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy.

Authors:  Takeshi Omae; Keito Koh; Masateru Kumemura; Sonoko Sakuraba; Yosuke Katsuda
Journal:  J Anesth       Date:  2019-05-08       Impact factor: 2.078

2.  Intracranial hemorrhage during administration of a novel oral anticoagulant.

Authors:  Akira Tempaku
Journal:  J Rural Med       Date:  2016-12-01

3.  Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.

Authors:  Shigeo Horinaka; Rie Sugawara; Yutaka Yonezawa; Toshihiko Ishimitsu
Journal:  Br J Clin Pharmacol       Date:  2017-10-18       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.